多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较

董佳佳; 章斌; 董佳佳; 章斌

doi:10.3760/cma.j.issn.1673-4114.2014.06.018

[1]

周纯武, 李二妮.乳腺影像学发展历程及展望[J].中华放射学杂志, 2013, 47增刊: 27-29. doi: 10.3760/cma.j.issn.1005-1201.2013.z1.008

[2]

田荣华, 王艳, 汪娇, 等.钼靶X线对乳腺癌的诊断(附174例分析)[J].实用放射学杂志, 2011, 27(11): 1670-1672. doi: 10.3969/j.issn.1002-1671.2011.11.015

[3]

张洪涛, 赵一冰, 宋培记, 等.钼靶乳腺摄像在乳腺癌新辅助化疗疗效评价中的应用[J].军事医学, 2012, 36(8): 616-618. doi: 10.3969/j.issn.1674-9960.2012.08.016

[4]

Sperber F, Weinstein Y, Sarid D, et al. Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer[J]. Isr Med Assoc J, 2006, 8(5): 342-346.

[5]

夏晓天, 张永学.影像学检查在乳腺癌的诊断及疗效评估中的应用价值[J].国际放射医学核医学杂志, 2010, 34(4): 242-246, 249. doi: 10.3760/cma.j.issn.1673-4114.2010.04.014

[6]

Belli P, Costantini M, Malaspina C, et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy[J]. Clin Radiol, 2006, 61(11): 946-953. doi: 10.1016/j.crad.2006.07.004

[7]

Choi JH, Lim HJ, Lee SK, et al. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging[J]. J Sur Oncol, 2010, 102(5): 392-397.

[8]

Wu LM, HuJN, Gu HY, et al. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?[J]. Breast Cancer Res Treat, 2012, 135(1): 17-28.

[9]

袁建伟, 杨劼, 贺小红, 等.乳腺癌¹⁸F-FDG PET/CT和3. 0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志, 2013, 37(2): 84-87. doi: 10.3760/cma.j.issn.1673-4114.2013.02.006

[10]

郁骐襄, 陈小松, 沈坤炜. MRI在乳腺癌新辅助化疗中的地位[J].中华外科学杂志, 2011, 49(9): 845-847.

[11]

李蔚萍, 苗华栋, 唐健雄, 等.多排螺旋CT在乳腺癌诊断和术前评估中的价值[J].中华普通外科杂志, 2011, 26(1): 29-32. doi: 10.3760/cma.j.issn.1007-631X.2011.01.010

[12]

徐民, 纪建松, 卢陈英, 等.多层螺旋CT对进展期乳腺癌新辅助化疗的疗效评估[J].医学影像学杂志, 2012, 22(10): 1677-1680. doi: 10.3969/j.issn.1006-9011.2012.10.025

[13]

Tozaki M, Kobayashi T, Uno S, et al. Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern[J]. AJR Am J Roentgenol, 2006, 186(2): 431-439. doi: 10.2214/AJR.04.1520

[14]

黄朝光, 辛付莹, 鲁毅.彩超、钼靶评价新辅助化疗疗效的应用研究[J].中外医疗, 2011(17): 181. doi: 10.3969/j.issn.1674-0742.2011.17.140

[15]

Chen M, Zhan WW, Han BS, et al. Accuracy of physical examination, ultrasonography, and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer[J]. Chin Med J(Engl), 2012, 120: 1862-1866.

[16]

Cao X, Xue J, Zhao B, et al. Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer[J]. Ultrasound Med Biol, 2012, 38(12): 2065-2071. doi: 10.1016/j.ultrasmedbio.2012.07.027

[17]

陈谦谦, 薛恩生.超声、钼靶X线联合MRI在乳腺癌术前评价中的应用[J].中国医学影像学杂志, 2012, 20(2): 148-152. doi: 10.3969/j.issn.1005-5185.2012.02.023

[18]

Dietl B, Marienhagen J. The therapeutic impact of ¹⁸F-FDG whole body PET A radiooncologist's view[J]. Nuklearmedizin, 2005, 44(1): 8-14.

[19]

席云, 张敏, 郭睿, 等. ¹⁸F-FDG PET或PET/CT评估乳腺癌新辅助化疗疗效价值的meta分析[J].中华核医学与分子影像杂志, 2012, 32(3): 192-197. doi: 10.3760/cma.j.issn.2095-2848.2012.03.008

[20]

贾丽, 于金明, 王仁本, 等. ¹⁸F-FDG PET/CT对乳腺癌新辅助化疗疗效预测的价值[J].中国肿瘤临床与康复, 2006, 13(3): 215-218. doi: 10.3969/j.issn.1005-8664.2006.03.009

[21]

Humbert O, Berriolo-Riedinger A, Riedinger JM, et al. Changes in ¹⁸F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes[J]. Ann Oncol, 2012, 23(10): 2572-2577. doi: 10.1093/annonc/mds071

[22]

Kumar A, Kumar R, Seenu V, et al. The role of ¹⁸F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer[J]. Eur Radiol, 2009, 19(6): 1347-1357. doi: 10.1007/s00330-009-1303-z

[23]

Andrade WP, Lima EN, Osório CA, et al. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?[J]. Eur J Sur Onco, 2013, 39(12): 1358-1363. doi: 10.1016/j.ejso.2013.08.025

[24]

Koolen BB, Valdés Olmos RA, Elkhuizen PH, et al. Locoregional lymph node involvement on ¹⁸F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy[J]. Breast Cancer Res Treat. 2012, 135(1): 231-240. doi: 10.1007/s10549-012-2179-1

[25]

Koolen BB, Vranckhen Peeters MJ, Aukema TS, et al. ¹⁸F-FDG PET/CT as a staging procedure in primary stage Ⅱ and Ⅲ breast cancer: comparison with conventional imaging techniques[J]. Breast Cancer Res Treat, 2012, 131(1): 117-126.

[26]

吴建伟, 高红, 艾书跃, 等. PET/CT对乳腺癌术后转移的诊断意义[J].医学研究生学报, 2013, 26(1): 41-44. doi: 10.3969/j.issn.1008-8199.2013.01.012

[27]

Smyezek-Gargya B, Fersis N, Dittmann H, et al. PET with[¹⁸F]fluorothymidine for imaging of primary breast cancer: a pilot study[J]. Eur J Nucl Med Mol Imaging, 2004, 31(5): 720-724. doi: 10.1007/s00259-004-1462-8

[28]

van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of ¹⁸F-FLT and ¹⁸F-FDG for differentiating tumor from inflammation in a rodent model[J]. J Nucl Med, 2004, 45(4): 695-700.

[29]

Yamamoto Y, Nishiyama Y, Ishikawa S, et al. 3'-Deoxy-3'-¹⁸F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-¹⁸f-fluoro-D-glucose[J]. J Compute Assist Tomogr, 2008, 32(3): 432-437. doi: 10.1097/RCT.0b013e3180980db9

[30]

陈雷, 柳曦. ¹⁸F-FDG和¹⁸F-FLT的正电子发射断层显像对肿瘤放化疗疗效评价的实验研究[J].中国医药导报, 2013, 10(18): 41-43. doi: 10.3969/j.issn.1673-7210.2013.18.014

[31]

Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and ¹⁸F-fluoroestradiol[J]. J Nucl Med, 2008, 49(3): 367-374.

[32]

Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy[J]. Eur J Nucl Med, 1999, 26(1): 51-56.

[33]

Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer[J]. J Clin Oncol, 2001, 19(11): 2797-2803. doi: 10.1200/JCO.2001.19.11.2797

[34]

Brepoels L, Stroobants S, Verhoef G, et al. ¹⁸F-FDG and ¹⁸F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model[J]. J Nucl Med, 2009, 50(7): 1102-1109. doi: 10.2967/jnumed.109.062208

[35]

Song SL, Liu JJ, Huang G, et al. Changes in ¹⁸F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model[J]. J Nucl Med, 2008, 49(2): 303-309.